Clinical Report: Therapeutic Focus on Cryopreserved Amniotic Membrane

Overview

Cryopreserved amniotic membrane (CAM360 AG) demonstrates significant healing properties for ocular surface diseases, including dry eye disease and neurotrophic keratitis. Its anti-inflammatory and patient-friendly application features enhance treatment outcomes and patient comfort.

Background

The management of ocular surface diseases, particularly dry eye disease (DED) and neurotrophic keratitis (NK), is crucial for improving patient quality of life. Cryopreserved amniotic membrane offers a novel therapeutic option that combines efficacy with ease of use, making it a valuable addition to treatment protocols. Understanding its benefits and application can enhance clinical practice and patient outcomes.

Data Highlights

Key Findings

• CAM360 AG exhibits anti-inflammatory, anti-scarring, and antiangiogenic properties.
• It has been shown to reduce signs and symptoms of dry eye disease effectively.
• Patients with neurotrophic keratitis experienced a return to normal corneal sensitivity after treatment.
• The membrane's adhesive properties enhance patient comfort and ease of application.
• Working-age patients appreciate the quick application process and short downtime associated with CAM360 AG.

Clinical Implications

Incorporating CAM360 AG into treatment regimens for DED and NK can lead to improved patient outcomes and satisfaction. Clinicians should consider the unique properties of CAM360 AG to optimize treatment protocols and enhance patient comfort.

Conclusion

Cryopreserved amniotic membrane represents a promising therapeutic option for ocular surface diseases, offering both efficacy and convenience. Its integration into clinical practice may significantly benefit patients suffering from these conditions.

References

1. McDonald M, Janik SB, Bowden FW, et al., Clin Ophthalmol, 2023 -- Association of Treatment Duration and Clinical Outcomes in Dry Eye Treatment with Sutureless Cryopreserved Amniotic Membrane
2. McDonald MB, Sheha H, Tighe S, et al., Clin Ophthalmol, 2018 -- Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study
3. John T, Tighe S, Sheha H, et al., J Ophthalmol, 2017 -- Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease
4. Cheng AM, Zhao D, Chen R, et al., Ocul Surf, 2016 -- Accelerated Restoration of Ocular Surface Health in Dry Eye Disease by Self-Retained Cryopreserved Amniotic Membrane
5. Retinal Physician — In Situ Retinal Regeneration
6. Retinal Physician — Counseling Patients About Gene Therapy
7. Knee Surgery, Sports Traumatology, Arthroscopy — Regenerative Joint Therapy Utilizing Cell-Based Approaches: An Emerging Focus
8. Ophthalmology Management — BIO-TISSUE: Pioneering Regenerative Therapy for Ocular Disease
9. Dry Eye Syndrome Preferred Practice Pattern®
10. Efficacy of Fresh Versus Preserved Amniotic Membrane Grafts for Ocular Surface Reconstruction: Meta-analysis
11. Microsoft Word - OXERVATE PI December 2024